Obesity has been linked to reduced bone strength, and the canonical Wnt signaling pathway plays a crucial role in regulating mesenchymal stem cell differentiation into either osteoblasts or adipocytes. Previous research has shown that obesity-induced upregulation of Dkk1, a Wnt inhibitor produced by osteoblasts, drives bone loss. However, the role of adipocyte-produced Dkk1 in bone remodeling and obesity-induced bone loss remains unclear. In this study, we investigated the influence of adipogenic Dkk1 on bone homeostasis and obesity-induced bone loss in mice. Using tamoxifen administration, we induced deletion of Dkk1 in adipocytes in male Dkk1fl/fl;AdipoQcreERT2 (Dkk1 cKO) mice and fed Dkk1fl/fl;AdipoQcre-positive mice and controls a high-fat diet (HFD) for 12 weeks. Bone and fat mass were analyzed at 12 and 20 weeks of age. In this study we found that 12-week-old male mice without adipogenic Dkk1 had a significant increase in trabecular bone volume in the vertebrae and femoral bones. However, there was no difference in bone volume between controls and Dkk1fl/fl;AdipoQcre-positive mice at 20 weeks of age. Additionally, Dkk1fl/fl;AdipoQcre-positive mice were not protected from HFD-induced bone loss. Even though Sost, another important Wnt inhibitor, was expressed at lower levels in bone from Dkk1-deficient mice fed with HFD compared to Dkk1-sufficient mice, this did not prevent the HFD-induced suppression of bone formation. Therefore, adipogenic Dkk1 may play a transient role in bone mass regulation during adolescence, but it does not contribute to bone homeostasis or obesity-induced bone loss later in life.